{"organizations": [], "uuid": "de05cdc48237375d73960167572e8e0aaf067e93", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-tesaro-says-anaphylactic-shock-oth/brief-tesaro-says-anaphylactic-shock-other-hypersensitivity-reactions-reported-for-varubi-injectable-emulsion-idUSASB0C0VC", "country": "US", "domain_rank": 408, "title": "BRIEF-Tesaro Says Anaphylactic Shock, Other Hypersensitivity Reactions Reported For Varubi Injectable Emulsion", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-13T00:53:00.000+02:00", "replies_count": 0, "uuid": "de05cdc48237375d73960167572e8e0aaf067e93"}, "author": "", "url": "https://www.reuters.com/article/brief-tesaro-says-anaphylactic-shock-oth/brief-tesaro-says-anaphylactic-shock-other-hypersensitivity-reactions-reported-for-varubi-injectable-emulsion-idUSASB0C0VC", "ord_in_thread": 0, "title": "BRIEF-Tesaro Says Anaphylactic Shock, Other Hypersensitivity Reactions Reported For Varubi Injectable Emulsion", "locations": [], "entities": {"persons": [{"name": "other hyp", "sentiment": "negative"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "tesaro inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "varubi injectable emulsion reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 12 (Reuters) - Tesaro Inc:\n* TESARO ANNOUNCES UPDATES TO THE U.S. PRESCRIBING INFORMATION FOR VARUBI (ROLAPITANT) INJECTABLE EMULSION\n* TESARO INC - CHANGES TO LABELING INCLUDE MODIFICATIONS TO CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, AND ADVERSE REACTIONS SECTIONS\n* TESARO - ANAPHYLAXIS, ANAPHYLACTIC SHOCK HAVE BEEN REPORTED FOR VARUBI INJECTABLE EMULSION POSTMARKETING SETTING, SOME REQUIRING HOSPITALIZATION\n* TESARO - OTHER “SERIOUS” HYPERSENSITIVITY REACTIONS HAVE ALSO BEEN REPORTED FOR VARUBI INJECTABLE EMULSION POSTMARKETING SETTING\n* TESARO - MOST REACTIONS HAVE OCCURRED DURING OR SOON AFTER INFUSION OF VARUBI INJECTABLE EMULSION AND WITHIN FIRST FEW MINUTES OF ADMINISTRATION Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-01-13T00:53:00.000+02:00", "crawled": "2018-01-13T01:13:50.011+02:00", "highlightTitle": ""}